이노보테라퓨틱스 InnovoTherapeutics

HISTORY

History

2024
- 08
  - Succeeded in Phase 2 clinical trial of INV-001 by MFDS* (Scar treatment) * Ministry of Food and Drug Safety
- 01
  - Received a DIPS** 1000+ grant ** Deep-Tech Incubator Project for Startups
2023
- 10
  - Received a KDDF*** grant (INV-004, preclinical) *** Korea Drug Development Fund
- 09
  - Certified as a Company of Excellence in Employee Invention Promotion (2023.09 ~2025.09)
- 07
  - Received a National Center for Cosmetics R&D grant (INC-001)
- 06
  - Received a KDDF grant (INV-008)
- 04
  - Received a DIPS 1000+ grant
2022
- 11
  - Approved phase 2 IND by MFDS (Scar treatment)
- 09
  - Received a KDDF grant (INV-101, phase 1)
- 03
  - Approved phase 1 IND by US FDA (Ulcerative Colitis)
2021
- 11
  - Completed Series B funding
- 10
  - Received a KDDF grant (INV-101, pre-clinical)
- 09
  - Received a KDDF grant (INV-005)
- 06
  - Headquarter relocated (Mapo-gu, Seoul, Republic of Korea)
2020
- 12
  - Received a Ministry of SMEs and Startups grant (INV-006)
- 09
  - Received an Innovative Sector Startup Package (BIG3) grant
- 01
  - R&D center established (Youseong-gu, Daejeon, Republic of Korea)
2019
- 12
  - Completed Series A funding
- 06
  - In-licensing of IBD
- 03
  - Incorporated (Mapo-gu, Seoul, Republic of Korea)